AgeX Therapeutics Inkomsten in het verleden
Verleden criteriumcontroles 0/6
AgeX Therapeutics's earnings have been declining at an average annual rate of -2.6%, while the Biotechs industry saw earnings growing at 14.5% annually. Revenues have been declining at an average rate of 59.9% per year.
Belangrijke informatie
-2.6%
Groei van de winst
-1.5%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 17.0% |
| Inkomstengroei | -59.9% |
| Rendement op eigen vermogen | -276.4% |
| Nettomarge | -10,424.6% |
| Laatste winstupdate | 31 Dec 2023 |
Recente prestatie-updates uit het verleden
Opbrengsten en kosten
Hoe AgeX Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -15 | 9 | 1 |
| 30 Sep 23 | 0 | -14 | 7 | 1 |
| 30 Jun 23 | 0 | -11 | 7 | 1 |
| 31 Mar 23 | 0 | -11 | 6 | 1 |
| 31 Dec 22 | 0 | -10 | 6 | 1 |
| 30 Sep 22 | 0 | -10 | 6 | 1 |
| 30 Jun 22 | 0 | -9 | 6 | 1 |
| 31 Mar 22 | 0 | -9 | 6 | 2 |
| 31 Dec 21 | 0 | -9 | 7 | 1 |
| 30 Sep 21 | 0 | -9 | 7 | 2 |
| 30 Jun 21 | 0 | -9 | 7 | 3 |
| 31 Mar 21 | 0 | -9 | 7 | 3 |
| 31 Dec 20 | 0 | -10 | 7 | 4 |
| 30 Sep 20 | 1 | -11 | 7 | 4 |
| 30 Jun 20 | 1 | -11 | 7 | 5 |
| 31 Mar 20 | 1 | -12 | 8 | 6 |
| 31 Dec 19 | 2 | -12 | 8 | 6 |
| 30 Sep 19 | 1 | -13 | 8 | 6 |
| 30 Jun 19 | 1 | -12 | 7 | 6 |
| 31 Mar 19 | 2 | -10 | 6 | 6 |
| 31 Dec 18 | 1 | -8 | 6 | 6 |
| 30 Sep 18 | 2 | -6 | 4 | 6 |
| 30 Jun 18 | 2 | -6 | 4 | 6 |
| 31 Mar 18 | 1 | -4 | 4 | 6 |
| 31 Dec 17 | 1 | -7 | 4 | 6 |
| 31 Dec 16 | 2 | -15 | 6 | 8 |
Kwaliteitswinsten: AGE is currently unprofitable.
Groeiende winstmarge: AGE is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: AGE is unprofitable, and losses have increased over the past 5 years at a rate of 2.6% per year.
Versnelling van de groei: Unable to compare AGE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: AGE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Rendement op eigen vermogen
Hoge ROE: AGE has a negative Return on Equity (-276.43%), as it is currently unprofitable.